Matcha and the benefits of longevity, according to an expert | Good + good


[ad_1]

LLongevity is not about living as long as possible, but about having a high quality of life throughout old age. And one of the best ways to improve longevity is through what you eat and drink. Dr David Sinclair, PhD, Harvard professor of anti-aging and author of Lifetime, recently took to Instagram to share her favorite hot drink: matcha. Matcha is made by grinding green tea leaves into a powder, and it has been served in Japan, China, and Korea since the 12th century. Dr Sinclair credits nutritionist to recently switch to matcha and its longevity benefits Serena poon.

The connection between matcha and longevity is in the tea’s abundance of antioxidants, but Dr Sinclair says it’s not even tea’s best superpower. “One of the healthiest drinks in the world is matcha. But not because of the antioxidants. It’s because of special plant molecules that we have named xenoormetins, made when plants are grown under unfavorable conditions,” says he in his Instagram post. “When we ingest them, they strengthen our survival defenses which fight against disease and aging.” Matcha is grown in the shade, which stresses the plants and causes them to make active compounds, says Dr. Sinclair.

Drinking matcha has many health benefits. It helps protect the kidneys, improve memory, and reduce inflammation. Matcha also has a high concentration of a compound called epigallocatechin gallate (ECGC). “The EGCG concentration of matcha is 137 times that of China Green Tips green tea and more than three times the highest value in the literature for other green teas,” said Dr. Sinclair. EGCG helps prevent cell damage and slows down aging.

In summary: “Matcha is now my hot drink of choice,” says Dr. Sinclair. It might be yours too.

Oh hi! You look like someone who loves free workouts, discounts for top wellness brands, and exclusive Well + Good content. Subscribe to Well +, our online community of wellness insiders, and unlock your rewards instantly.


[ad_2]

Comments are closed.